Back to Peptides

Frag 176-191

Growth Factors & Muscle Building

Frag 176-191 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH). It has been studied in preclinical models for its ability to modulate fat metabolism without the insulin or IGF-1 signaling typically associated with full-length hGH. It is not considered anabolic but is of interest for its targeted lipolytic properties in laboratory research.

Reconstitute
2 mL BAC + 5mg vial
25 mcg/unit
Daily Range
250–1000 mcg Subcutaneous (SQ)
1–2x daily (AM fasted and/or pre-bed)
Standard Dose
500 mcg
Cycle
4–8 weeks
then reassess
Frag 176-191hGH fragmentfat loss peptidelipolysisGH derivative

Dosing & Reconstitution Guide

In preclinical studies, Frag 176-191 has been administered at 250–500 mcg per day via subcutaneous injection. These protocols are investigational and not approved for human or veterinary application.

Standard / Gradual Approach

5mg Vialstandard
PhaseDoseVolume
Weeks 1–2250 mcg SQ 1x daily (AM fasted)10 units (0.10 mL)
Weeks 3–4500 mcg SQ 1x daily (AM fasted)20 units (0.20 mL)
Weeks 5–8500 mcg SQ 2x daily (AM + pre-bed)20 units per injection

Protocol Summary

Subcutaneous (SQ): 1–2x daily (AM fasted and/or pre-bed) · Dose range 250–1000 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Inject 1–2x daily for 4–8 weeks. Optional maintenance: 500 mcg daily 3x/week. Rotate injection sites to avoid irritation.

🧪 Quick Start

Vial Size
5 mg
BAC Water
2 mL
Concentration
2500 mcg/unit

Potential Benefits & Use Cases

Frag 176-191 is a research-use-only peptide. It is not approved for human or veterinary use. This information is for scientific and educational purposes only.
Studied for selective fat metabolism support in adipose tissue
Does not significantly impact insulin resistance or blood sugar levels in preclinical data
Explored as a non-anabolic fragment for weight-related endpoints
Evaluated for body composition effects in rodent obesity models
Research interest in synergy with metabolic or mitochondrial peptides
Clinical data Strong preclinical Limited data

Mechanism of Action

→Derived from the C-terminal region (176-191) of human growth hormone (hGH)
→Activates GH receptor-related fat-burning pathways without affecting IGF-1 or glucose metabolism
→Stimulates lipolysis in adipocytes, especially in abdominal and visceral fat stores
→Reduces lipogenesis and improves mitochondrial fat oxidation

Lifestyle & Optimization

timing

Inject fasted — wait 20–30 minutes before eating. Avoid carbs/insulin spikes around injection time as insulin blunts Frag's effects.

diet

Caloric deficit amplifies results. Avoid high-carb meals around injection time.

exercise

Combine with fasted morning cardio (LISS 30–45 min) for enhanced lipolysis.

sleep

Adequate rest for metabolic recovery.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
The GH Fragment 176-191 Enhances Lipolysis in Adipose TissueReference
A Fragment of hGH That Reduces Adiposity Without IGF-1 IncreaseReference
Targeting Visceral Adiposity with GH Fragment TherapyReview

Side Effects & Safety

Common Side Effects

• Injection site irritation
• Mild hunger increase

Contraindications & Warnings

• Avoid use alongside insulin or IGF-1 therapies unless supervised
• Not for pediatric or muscle-growth-focused use

Long-Term Safety Data

• No adverse effects observed in short-term animal studies; long-term safety in humans unverified

🧮 Dose Calculator

Concentration
25.0
mcg/unit
Draw Volume
20
units (0.200 mL)
For a 500 mcg dose, draw 20 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High; best injected into abdominal fat for localized effect
Oral Administration
Not bioavailable due to peptide degradation
Half-Life
Approximately 30 minutes
Degradation
Metabolized in liver and blood via proteases
Tissue Specificity
Targets adipose tissue with minimal systemic growth impact
⚗️

Peptide Details

Molecular Weight
1817.1
Formula
C78H125N23O23S2
Sequence
Thr-Ser-Ile-Cys-Ser-Val-Glu-Gln-Gly-Glu-Arg-Ala-Arg-Leu-Asp-Arg-Ile-Arg-Glu-Lys-Ala-Gly-Phe-Ser
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
Store at -20°C or 2–8°C. Protect from light. Stable for 12+ months lyophilized.
Reconstituted (Mixed)
Refrigerate at 2–8°C. Use within 3–4 weeks. Avoid freeze-thaw cycles.